Anti-PD-1 /CTLA-4 Antibody (Cadonilimab)
Catalog No.
F2106
Anti-PD-1 /CTLA-4 Antibody (Cadonilimab)
Featured Products
Cadonilimab is a bispecific antibody developed by a Chinese biopharmaceutical company. It consists of two fragments of monoclonal antibodies, targeting PD-1 and CTLA-4 respectively. By blocking these two immune checkpoints at the same time, Cadonilimab is able to enhance the anti-tumor activity of T cells and is mainly used to treat various types of cancer.
Dry ice
2394841-59-7
-80°C
2 years
Liquid
1 mg/mL
For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
CHO
AK104
100 mM Pro 20 mM Arg pH 5.0.
Human
Unconjugated
Monoclonal
Protein A
IgG1
ELISA, FACS, Kinetics, Functional assay, Animal Model
PD-1 /CTLA-4
Please avoid freeze-thaw cycles.